Lemonaid Health→23andMe
Acquisition · Cash and stock · ME · announced Oct 22, 2021
Announced
Oct 22, 2021
Closed
Nov 1, 2021
Economics
Cash and stock
$400M purchase price (25% cash, 75% 23andMe Class A stock), subject to customary adjustments per SEC EX-99.1 (Oct 22, 2021)
Target
Lemonaid Health
Mental Health · Consumer wellness
HQ San Francisco, CA · Founded 2013
Telehealth platform with women's health focus
- SEC EDGAR EX-99.1 — 23andMe/Lemonaid merger agreement (Oct 22, 2021)
- Globe Newswire — acquisition closing (Nov 1, 2021)
- Crunchbase - crunchbase.com/organization/lemonaid-health
Acquirer
23andMe (ME)
General Wellness
HQ Sunnyvale, CA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Combined consumer genetics with telehealth and mail-order pharmacy to expand into personalized virtual care
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR EX-99.1 (23andMe–Lemonaid merger agreement, Oct 22, 2021)
SEC EDGAR filings (ticker locator)Secondary (press / IR)
Globe Newswire closing release (Nov 1, 2021)
Limitations
- $400M purchase price (25% cash, 75% 23andMe Class A stock), subject to customary adjustments per SEC EX-99.1 (Oct 22, 2021)
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Lemonaid Health (Mental Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.